SynthesisFrontiers in oncology2024
Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics for predicting microsatellite instability-high status in colorectal cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics.BMC medical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This meta-analysis aims to evaluate the diagnostic accuracy of magnetic resonance imaging (MRI) based radiomic features for predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastases. Methods: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, Scopus, Wanfang, and China National Knowledge Infrastructure (CNKI) for studies published up to April 30, 2024. We included those studies that utilized MRI-based radiomic features to detect EGFR mutations in NSCLC patients with brain metastases. Sensitivity, specificity, positive and negative likelihood ratios (PLR, NLR), and area under the curve (AUC) were calculated to evaluate the accuracy. Quality assessment was performed using the quality assessment of prognostic accuracy studies 2 (QUADAS-2) tool. Meta-analysis was conducted using random-effects models. Results: A total of 13 studies involving 2,348 patients were included. The pooled sensitivity and specificity of MRI-based radiomic features for detecting EGFR mutations were 0.86 (95% CI: 0.74-0.93) and 0.83 (95% CI: 0.72-0.91), respectively. The PLR and NLR were calculated as 5.14 (3.09, 8.55) and 0.17 (0.10, 0.31), respectively. Substantial heterogeneity was observed, with I² values exceeding 50% for all parameters. The AUC for the receiver operating characteristic analysis was 0.91 (95% CI: 0.88-0.93). Subgroup analysis indicated that deep learning models and studies conducted in Asian showed higher diagnostic accuracy compared to their respective counterparts. Conclusions: MRI-based radiomic features demonstrate a high potential for accurately detecting EGFR mutations in NSCLC patients with brain metastases, particularly when advanced deep learning techniques were employed. However, the variability in diagnostic performance across different studies underscores the need for standardized radiomic protocols to enhance reproducibility and clinical utility. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024544131.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.